PATENT Customer No. 22,852 Attorney Docket No. 06267.0128

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Matti KIVIKKO et al.  Application No.: 10/541,394  Filed: July 1, 2005  For: A METHOD FOR TREATING RENAL FAILURE  Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	In re Application of:	)
Filed: July 1, 2005  For: A METHOD FOR TREATING RENAL ) FAILURE  Commissioner for Patents P.O. Box 1450	Matti KIVIKKO et al.	) Group Art Unit: Unassigned
For: A METHOD FOR TREATING RENAL ) FAILURE )  Commissioner for Patents P.O. Box 1450	Application No.: 10/541,394	) Examiner: Unassigned
FAILURE )  Commissioner for Patents P.O. Box 1450	Filed: July 1, 2005	)
P.O. Box 1450		) )
	P.O. Box 1450	

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Attorney Docket No. 06267.0128 Application No. 10/541,394

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: March 29, 2006

Steven J. Scott Reg. No. 43,911

. IDS Form PTO/SB/08: Substitute for form 1449A/PTO			Comp	olete if Known	
				Application Number	10/541,394
	NFORMATIO	N DISCLO	SURE	Filing Date	July 1, 2005
	STATEMENT BY APPLICANT			First Named Inventor	Matti KIVIKKO
•	SIAIEMENI	DIAFFL	ICANI	Art Unit	UNASSIGNED
	(Use as many s	sheets as necessa	iry)	Examiner Name	UNASSIGNED
Sheet	1	of	1	Attorney Docket Number	06267.0128

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner	Cite No.1	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
Initials		Number-Kind Code <sup>2</sup> (if known)			Relevant Passages or Relevant Figures Appear	
		RE 38,102	29 Apr. 2003	Haikala et al.		
-						
	<u> </u>					
-						
			-			
	<del></del> -					

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation	
		WO 99/66932	29 Dec. 1999				

Examiner	kaminer   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,					
Initials	No.1	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation			
		J. Lilleberg et al., "Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with Left Ventricular Dysfunction," J. Cardiovasc Pharmacol, Vol. 26 (Suppl. 1), pages S63-S69 (1995)				
		Stig Sundberg et al., "Hemodynamic and Neurohumoral Effects of Levosimendan, a New Calcium Sensitizer, at Rest and During Exercise in Healthy Men," The American Journal of Cardiology, Vol. 75, pages 1061-1066 (1995)				
	-	Esa-Pekka Sandell et al., "Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart Failure," J Cardiovasc Pharmacol, Vol. 26 (Suppl. 1), pages S57-S62 (1995)				

Examiner	Date	
Signature	Considered	!

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.